ClinicalTrials.gg
CompletedNCT01499199Updated Feb 25, 2015Results posted

A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects

A Phase 3 interventional study of Dolutegravir in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-02-25.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

ING116070 is a Phase IIIb single-arm, open-label, multicenter study. The study will be conducted in approximately 14 HIV-1 infected antiretroviral therapy (ART)-naïve subjects. Subjects who fulfill eligibility requirements will receive dolutegravir (DTG) 50 mg once daily in combination with the fixed dose dual nucleoside reverse transcripatase inhibitor(NRTI) abacavir/lamivudine (ABC/3TC) for 96 weeks. One pair of pharmacokinetic (PK) samples in plasma and cerebral spinal fluid (CSF) (matching time) for determination of DTG concentration will be collected at Week 2 and Week 16. Samples for plasma HIV-1 RNA will be collected at Baseline and various time points throughout the study and samples for HIV-1 RNA levels in the CSF will be collected at Baseline, Week 2 and Week 16. Safety, additional measures of antiviral activity and development of viral resistance will also be evlauated. The primary analysis will take place after the last subject completes 16 weeks on therapy; additional analyses will be conducted after the last subject completes Weeks 2 and 96 (end of study).

Read the detailed description

ING116070 is a Phase IIIb single-arm, open-label, multicenter study. The study will be conducted in approximately 14 HIV-1 infected antiretroviral therapy (ART)-naïve subjects. Subjects who meet all screening requirements may enter the study and initiate treatment as soon as all screening procedures have been completed and results are available and on file. The 14-day screening period may be extended to 28 days to allow receipt of all Screening assessment results and to accommodate scheduling.

Subjects who fulfill eligibility requirements will receive dolutegravir (DTG) 50 mg once daily in combination with the fixed dose dual nucleoside reverse transcripatase inhibitor(NRTI) abacavir/lamivudine ABC/3TC for 96 weeks. One pair of pharmacokinetic (PK) samples in plasma and CSF (matching time) for determination of DTG concentration will be collected at Week 2 and Week 16. Samples for plasma HIV-1 RNA will be collected at Baseline and various time points throughout the study and samples for HIV-1 RNA levels in the CSF will be collected at Baseline, Week 2 and Week 16. Safety, additional measures of antiviral activity and development of viral resistance will also be evlauated. The primary analysis will take place after the last subject completes 16 weeks on therapy; additional analyses will be conducted after the last subject completes Weeks 2 and 96 (end of study).

Subjects are considered to have completed the study if they remain on therapy (i.e., have not permanently discontinued investigational product [IP]) and complete the Treatment Phase, including the Week 96 visit.

02

Conditions studied

  • Infection, Human Immunodeficiency Virus

Keywords

  • cerebrospinal fluid (CSF)
  • ART-naive
  • integrase inhibitor
  • dolutegravir
  • antiretroviral therapy naive
03

In context

Infections

2,096 studies on the registry are indexed under Infections; 364 are open to participants now.

This study's enrollment of 13 is below the median of 113 across 1,304 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -1 infected adults at least 18 years of age. Females are eligible to enter and participate in the study if she is (1) of non- or (2) of childbearing potential with a negative pregnancy test at Screening and Day 1 and agrees to use protocol-defined methods of birthcontrol while on the study.
  • HIV-1 infection as documented by Screening plasma HIV-1 RNA greater than or equal to 5000 copies/mL
  • greater than or equal to 200 cells/mm3
  • Antiretroviral-naive (less than or equal to 10 days of prior therapy with any antiretroviral agent following diagnosis of HIV-1 infection)
  • Signed and dated written is obtained from the subject or the subject's legal representative prior to screening
  • Documentation that the subject has been screened for, and is negative for the HLA-B*5701 allele
  • Is willing to undergo serial lumbar punctures

Exclusion criteria

Exclusion Criteria:

  • Relative or absolute to lumbar puncture, such as current coagulopathy, thrombocytopenia ( less than 50,000/microliter), hemophilia, or use of anticoagulant medication
  • Moderate or severe cognitive impairment
  • Women who are pregnant or breastfeeding
  • Any evidence of an active Center for Disease Control and Prevention (CDC) Category C disease, except cutaneous Kaposi's sarcoma not requiring systemic therapy or historic CD4+ cell levels less than 200cells/mm3
  • Subjects with any degree of hepatic impairment
  • Positive for at screening (+HbsAg), or an anticipated need for virus (HCV) therapy during the study
  • History or presence of allergy or intolerance to the study drugs or their components or drugs of their class
  • History of within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma; other localized malignancies require agreement between the investigator and the Study medical monitor for inclusion of the subject
  • Recent history (less than or equal to 3 months) of any upper or lower gastrointestinal bleed, with the exception of anal or rectal bleeding
  • Treatment with an -1 immunotherapeutic vaccine within 90 days of Screening
  • Treatment with any of the following agents within 28 days of Screening: radiation therapy, cytotoxic chemotherapeutic agents, any immunomodulators that alter immune responses
  • Treatment with any agent, except recognized ART as allowed above, with documented activity against HIV-1 in vitro within 28 days of first dose of IP
  • Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of IP
  • Any evidence of primary viral resistance based on the presence of any major resistance-associated mutation in the Screening result or, if known, any historical resistance test result. Note: retests of Screening genotypes are not allowed
  • Any verified Grade 4 laboratory abnormality (a single repeat test is allowed during the Screening period to verify a result). Any acute laboratory abnormality at Screening, which, in the opinion of the Investigator, would preclude the subject's participation in the study of an compound is exclusionary
  • (ALT) greater than 5 times the (ULN)
  • ALT greater than or equal to 3xULN and greater than or equal to 1.5xULN (with greater than 35% direct bilirubin)
  • Subject has of less than 50 mL/min via Cockroft-Gault method
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Dolutegravir 50mg Once Daily

    All subjects will receive 50mg dolutegravir once daily in combination with background antiretroviral therapy consisting of one abacavir/lamivudine fixed dose combination tablet once daily

    Drug: Dolutegravir

Interventions

06

What researchers measure

Primary outcomes

  1. The Ratio of Total and Unbound DTG Concentrations Between Cerebrospinal Fluid (CSF) and Plasma at Week 2 and Week 16

    Cerebrospinal fluid (CSF) is a clear, colorless bodily fluid produced in the choroid plexus of the brain. The CFS samples were collected at the Week 2 and Week 16 visits, within 1 hour of plasma pharmacokinetic (PK) sampling. The ratio (presented as a percentage) of CSF DTG concentration over paired plasma total DTG concentration (RCSF_plasma) was calculated at the Week 2 and Week 16 visits.

    Time frame: Week 2 and Week 16

  2. Total DTG Plasma Concentrations at Week 2 and Week 16

    Total plasma DTG concentrations were calculated at the Week 2 and Week 16 visits.

    Time frame: Week 2 and Week 16

  3. Unbound DTG Plasma Concentrations at Week 2 and Week 16

    Unbound (free, not bound to cellular proteins) plasma DTG concentrations were calculated at the Week 2 and Week 16 visits.

    Time frame: Week 2 and Week 16

  4. Plasma DTG Unbound Fraction at Week 2 and Week 16

    The unbound fraction of DTG in plasma (presented as a percentage of unbound \[i.e., free DTG not bound to cellular proteins\] DTG plasma concentration over paired plasma total DTG concentration) was calculated at the Week 2 and Week 16 visits.

    Time frame: Week 2 and Week 16

  5. DTG Concentrations in CSF at Weeks 2 and Week 16

    CSF is a clear, colorless bodily fluid produced in the choroid plexus of the brain. The CFS samples were collected at the Week 2 and Week 16 visits, within 1 hour of plasma PK sampling. DTG concentration in CSF were calculated at the Week 2 and Week 16 visits.

    Time frame: Week 2 and Week 16

Secondary outcomes

  1. Number of Participants With Plasma HIV-1 RNA <50 Copies Per Milliliter (c/mL) at Baseline and Weeks 2, 4, 8, 12, and 16

    HIV-1 RNA response in plasma was measured as the number of participants with HIV-1 RNA less than 50 c/mL at Baseline, Week 2, Week 4, Week 8, Week 12, and Week 16.

    Time frame: Baseline; Weeks 2, 4, 8, 12, and 16

  2. Absolute Values and Change From Baseline in Plasma Human Immunodeficiency Virus (HIV-1) Ribonucleic Acid (RNA) Levels at Weeks 2, 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, and 96

    The plasma samples were collected at the Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, and Week 96 visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Weeks 2, 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, and 96

  3. Number of Participants With CSF HIV-1 RNA <50 Copies/Milliliter (c/mL) at Baseline, Week 2, and Week 16

    The antiviral activity of dolutegravir in CSF over time was measured as the number of participants with HIV-1 RNA \<50 copies/milliliter (c/mL).

    Time frame: Baseline, Week 2, and Week 16

  4. Absolute Values and Change From Baseline in CSF HIV-1 RNA Levels at Week 2 and Week 16

    The antiviral activity of dolutegravir in CSF over time was measured as absolute values and change from Baseline in HIV-1 RNA levels in CSF at Week 2 and Week 16. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline, Week 2, and Week 16

  5. Number of Participants With the Indicated Number of Copies of HIV-1 RNA in Both the CSF and Plasma at Baseline, Week 2, and Week 16

    The relationship between HIV-1 RNA suppression in plasma and the CSF was measured as a comparison and as a change in the number of participants in the cross tabulation of \<50 copies/mL in plasma, \<50 copies/mL in CSF, \>=50 copies/mL in plasma, and \>=50 copies/mL in CSF at Baseline, Week 2, and Week 16.

    Time frame: Baseline, Week 2, and Week 16

  6. Pearson Correlation Between CSF DTG Concentration and Absolute Values and Change From Baseline (CFB) in CSF HIV-1 RNA at Week 2, Week 16, and Overall

    The Pearson Correlation Coefficient is a measure of the correlation between CSF DTG concentrations and absolute values/changes from Baseline in CSF HIV-1 RNA at Week 2 and Week 16. CSF HIV-1 RNA is measured as log10 copies per milliliter (copies/mL).

    Time frame: From Baseline to Week 16

  7. Absolute Values and Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Counts at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, and 96

    The absolute value for CD4+ cell count (cells per millimeters cubed \[mm\^3\]) was assessed at Baseline, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, and Week 96. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, and 96

  8. Absolute Values and Change From Baseline in Cluster of Differentiation 8+ (CD8+) Cell Counts at Weeks 4, 12, 16, 24, 48, and 96

    The absolute value for CD48+ cell count (cells per millimeters cubed \[mm\^3\]) was assessed at Baseline, Week 4, Week 12, Week 16, Week 24, Week 48, and Week 96. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Weeks 4, 12, 16, 24, 48, and 96

  9. Number of Participants With Post-Baseline HIV-1-associated Conditions, Including Recurrences

    The number of participants who reported a new or recurrent Centers for Disease Control and Prevention (CDC) Class B or Class C condition was assessed from Baseline though the date the last participant completed Week 96 + the follow-up visit (if applicable). Category (CAT) A: one or more of the following conditions (CON), without any CON listed in Categories B and C: asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have a clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C: the clinical CON listed in the AIDS surveillance case definition.

    Time frame: Baseline through the date the last participant completed Week 96 + follow-up visit (if applicable)

  10. The Numbers of Participants (Par.) With Clinical Adverse Events or Laboratory Abnormalities

    An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs/SAEs. Any abnormal laboratory test result (hematology, clinical chemistry, or urinalysis) or other safety assessments (e.g., electrocardiograms \[ECGs\], radiological scans, vital sign measurements), including those that worsen from Baseline, and were felt to be clinically significant in the medical and scientific judgment of the investigator, were recorded as AEs or SAEs. Clinically suspected cases of hypersensitivity to ABC were also SAEs.

    Time frame: Baseline (BL) through the date the last participant completed Week (W) 96 + the follow-up visit (if applicable)

  11. Number of Participants With Treatment-emergent Genotypic and Phenotypic Resistance to DTG and Other Antiretroviral Therapy (ART)

    The number of participants with treatment-emergent genotypic and phenotypic resistance to integrase inhibitors (INIs), nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transctiptase inhibitors (NNRTIs), and protease inhibitors (PIs) was assessed.

    Time frame: Baseline through the date the last participant completed Week 96

07

Results

Posted Nov 25, 2013

Participant flow

Participant flow — Overall Study
MilestoneDolutegravir 50 mg OD
Started13
Completed11
Not completed2
Withdrew: Adverse event1
Withdrew: Lack of efficacy1

Outcome measures

PrimaryThe Ratio of Total and Unbound DTG Concentrations Between Cerebrospinal Fluid (CSF) and Plasma at Week 2 and Week 16

Cerebrospinal fluid (CSF) is a clear, colorless bodily fluid produced in the choroid plexus of the brain. The CFS samples were collected at the Week 2 and Week 16 visits, within 1 hour of plasma pharmacokinetic (PK) sampling. The ratio (presented as a percentage) of CSF DTG concentration over paired plasma total DTG concentration (RCSF_plasma) was calculated at the Week 2 and Week 16 visits.

Time frame:
Week 2 and Week 16
Reported as:
Median · percentage
The Ratio of Total and Unbound DTG Concentrations Between Cerebrospinal Fluid (CSF) and Plasma at Week 2 and Week 16
percentageDolutegravir 50 mg OD
Week 2, n=110.516 (0.115 to 0.658)
Week 16, n=120.412 (0.299 to 2.04)
PrimaryTotal DTG Plasma Concentrations at Week 2 and Week 16

Total plasma DTG concentrations were calculated at the Week 2 and Week 16 visits.

Time frame:
Week 2 and Week 16
Reported as:
Median · Micrograms per milliliter (µg/mL)
Total DTG Plasma Concentrations at Week 2 and Week 16
Micrograms per milliliter (µg/mL)Dolutegravir 50 mg OD
Week 23.36 (2.09 to 5.28)
Week 163.21 (0.64 to 4.92)
PrimaryUnbound DTG Plasma Concentrations at Week 2 and Week 16

Unbound (free, not bound to cellular proteins) plasma DTG concentrations were calculated at the Week 2 and Week 16 visits.

Time frame:
Week 2 and Week 16
Reported as:
Median · Nanograms per milliliter (ng/mL)
Unbound DTG Plasma Concentrations at Week 2 and Week 16
Nanograms per milliliter (ng/mL)Dolutegravir 50 mg OD
Week 217.1 (10.3 to 24.0)
Week 1623.9 (3.81 to 32.1)
PrimaryPlasma DTG Unbound Fraction at Week 2 and Week 16

The unbound fraction of DTG in plasma (presented as a percentage of unbound \[i.e., free DTG not bound to cellular proteins\] DTG plasma concentration over paired plasma total DTG concentration) was calculated at the Week 2 and Week 16 visits.

Time frame:
Week 2 and Week 16
Reported as:
Median · Percentage
Plasma DTG Unbound Fraction at Week 2 and Week 16
PercentageDolutegravir 50 mg OD
Week 20.488 (0.333 to 0.655)
Week 160.701 (0.488 to 4.30)
PrimaryDTG Concentrations in CSF at Weeks 2 and Week 16

CSF is a clear, colorless bodily fluid produced in the choroid plexus of the brain. The CFS samples were collected at the Week 2 and Week 16 visits, within 1 hour of plasma PK sampling. DTG concentration in CSF were calculated at the Week 2 and Week 16 visits.

Time frame:
Week 2 and Week 16
Reported as:
Median · Nanograms per milliliter (ng/mL)
DTG Concentrations in CSF at Weeks 2 and Week 16
Nanograms per milliliter (ng/mL)Dolutegravir 50 mg OD
Week 2, n=1118.2 (4.0 to 23.2)
Week 16, n=1213.2 (3.7 to 18.3)
SecondaryNumber of Participants With Plasma HIV-1 RNA <50 Copies Per Milliliter (c/mL) at Baseline and Weeks 2, 4, 8, 12, and 16

HIV-1 RNA response in plasma was measured as the number of participants with HIV-1 RNA less than 50 c/mL at Baseline, Week 2, Week 4, Week 8, Week 12, and Week 16.

Time frame:
Baseline; Weeks 2, 4, 8, 12, and 16
Reported as:
Number · participants
Number of Participants With Plasma HIV-1 RNA <50 Copies Per Milliliter (c/mL) at Baseline and Weeks 2, 4, 8, 12, and 16
participantsDolutegravir 50 mg OD
Baseline0
Week 24
Week 46
Week 88
Week 1210
Week 1610
SecondaryAbsolute Values and Change From Baseline in Plasma Human Immunodeficiency Virus (HIV-1) Ribonucleic Acid (RNA) Levels at Weeks 2, 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, and 96

The plasma samples were collected at the Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, and Week 96 visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Weeks 2, 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Median · log10 copies/mL
Absolute Values and Change From Baseline in Plasma Human Immunodeficiency Virus (HIV-1) Ribonucleic Acid (RNA) Levels at Weeks 2, 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, and 96
log10 copies/mLDolutegravir 50 mg OD
Absolute value, Baseline, n=134.73 (3.60 to 6.57)
Absolute value, Week 2, n=122.05 (1.59 to 2.99)
Change from Baseline, Week 2, n=12-2.53 (-3.70 to -2.01)
Absolute value, Week 4, n=121.67 (1.59 to 2.49)
Change from Baseline, Week 4, n=12-3.04 (-4.08 to -2.01)
Absolute Value, Week 8, n=121.59 (1.59 to 2.48)
Change from Baseline, Week 8, n=12-3.10 (-4.09 to -2.01)
Absolute value, Week 12, n=121.59 (1.59 to 2.36)
Change from Baseline, Week 12, n=12-3.04 (-4.20 to -2.01)
Absolute value, Week 16, n=121.59 (1.59 to 2.37)
Change from Baseline, Week 16, n=12-3.04 (-4.19 to -2.01)
Absolute Value, Week 24, n=121.59 (1.59 to 2.21)
Change from Baseline, Week 24, n=12-3.11 (-4.35 to -2.01)
Absolute value, Week 36, n=111.59 (1.59 to 1.62)
Change from Baseline, Week 36, n=11-3.08 (-3.89 to -2.01)
Absolute value, Week 48, n=111.59 (1.59 to 2.10)
Change from Baseline, Week 48, n=11-3.00 (-3.78 to -2.01)
Absolute value, Week 60, n=111.59 (1.59 to 2.19)
Change from Baseline, Week 60, n=11-3.00 (-3.89 to -2.01)
Absolute value, Week 72, n=111.59 (1.59 to 2.01)
Change from Baseline, Week 72, n=11-3.08 (-3.78 to -2.01)
Absolute value, Week 84, n=111.59 (1.59 to 1.72)
Change from Baseline, Week 84, n=11-3.08 (-3.89 to -1.88)
Absolute value, Week 96, n=111.59 (1.59 to 3.05)
Change from Baseline, Week 96, n=11-3.08 (-3.78 to -0.55)
SecondaryNumber of Participants With CSF HIV-1 RNA <50 Copies/Milliliter (c/mL) at Baseline, Week 2, and Week 16

The antiviral activity of dolutegravir in CSF over time was measured as the number of participants with HIV-1 RNA \<50 copies/milliliter (c/mL).

Time frame:
Baseline, Week 2, and Week 16
Reported as:
Number · participants
Number of Participants With CSF HIV-1 RNA <50 Copies/Milliliter (c/mL) at Baseline, Week 2, and Week 16
participantsDolutegravir 50 mg OD
Baseline, n=131
Week 2, n=127
Week 16, n=1111
SecondaryAbsolute Values and Change From Baseline in CSF HIV-1 RNA Levels at Week 2 and Week 16

The antiviral activity of dolutegravir in CSF over time was measured as absolute values and change from Baseline in HIV-1 RNA levels in CSF at Week 2 and Week 16. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline, Week 2, and Week 16
Reported as:
Median · log10 c/mL
Absolute Values and Change From Baseline in CSF HIV-1 RNA Levels at Week 2 and Week 16
log10 c/mLDolutegravir 50 mg OD
Absolute value, Baseline, n=133.64 (1.46 to 5.60)
Absolute value, Week 2, n=120.98 (0.00 to 3.30)
Change from Baseline, Week 2, n=12-2.19 (-3.11 to -1.29)
Absolute value, Week 16, n=110.00 (0.00 to 0.70)
Change from Baseline, Week 16, n=11-3.42 (-5.60 to -1.46)
SecondaryNumber of Participants With the Indicated Number of Copies of HIV-1 RNA in Both the CSF and Plasma at Baseline, Week 2, and Week 16

The relationship between HIV-1 RNA suppression in plasma and the CSF was measured as a comparison and as a change in the number of participants in the cross tabulation of \<50 copies/mL in plasma, \<50 copies/mL in CSF, \>=50 copies/mL in plasma, and \>=50 copies/mL in CSF at Baseline, Week 2, and Week 16.

Time frame:
Baseline, Week 2, and Week 16
Reported as:
Number · participants
Number of Participants With the Indicated Number of Copies of HIV-1 RNA in Both the CSF and Plasma at Baseline, Week 2, and Week 16
participantsDolutegravir 50 mg OD
Baseline, CSF<50 c/mL, Plasma<50 c/mL, n=130
Baseline, CSF<50 c/mL, Plasma>=50 c/mL, n=131
Baseline, CSF>=50 c/mL, Plasma<50 c/mL, n=130
Baseline, CSF>=50 c/mL, Plasma>=50 c/mL, n=1312
Week 2, CSF<50 c/mL, Plasma<50 c/mL, n=124
Week 2, CSF<50 c/mL, Plasma>=50 c/mL, n=123
Week 2, CSF>=50 c/mL, Plasma<50 c/mL, n=120
Week 2, CSF>=50 c/mL, Plasma>=50 c/mL, n=125
Week 16, CSF<50 c/mL, Plasma<50 c/mL, n=119
Week 16, CSF<50 c/mL, Plasma>=50 c/mL, n=112
Week 16, CSF>=50 c/mL, Plasma<50 c/mL, n=110
Week 16, CSF>=50 c/mL, Plasma>=50 c/mL, n=110
SecondaryPearson Correlation Between CSF DTG Concentration and Absolute Values and Change From Baseline (CFB) in CSF HIV-1 RNA at Week 2, Week 16, and Overall

The Pearson Correlation Coefficient is a measure of the correlation between CSF DTG concentrations and absolute values/changes from Baseline in CSF HIV-1 RNA at Week 2 and Week 16. CSF HIV-1 RNA is measured as log10 copies per milliliter (copies/mL).

Time frame:
From Baseline to Week 16
Reported as:
Mean · Pearson Correlation Coefficient
Pearson Correlation Between CSF DTG Concentration and Absolute Values and Change From Baseline (CFB) in CSF HIV-1 RNA at Week 2, Week 16, and Overall
Pearson Correlation CoefficientDolutegravir 50 mg OD
Week 2, Absolute Log10 CSF HIV-1 RNA, n=110.567 (0.062 to 0.841)
Week 2, CFB Log10 CSF HIV-1, n=110.007 (-0.518 to 0.529)
Week 16, Absolute Log10 CSF HIV-1 RNA, n=11-0.775 (-0.924 to -0.423)
Week 16, CFB Log10 CSF HIV-1, n=11-0.354 (-0.740 to 0.209)
Overall, Absolute Log10 CSF HIV-1 RNA, n=110.517 (0.193 to 0.740)
Overall, CFB Log10 CSF HIV-1, n=110.106 (-0.265 to 0.449)
SecondaryAbsolute Values and Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Counts at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, and 96

The absolute value for CD4+ cell count (cells per millimeters cubed \[mm\^3\]) was assessed at Baseline, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, and Week 96. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Median · cells/mm^3
Absolute Values and Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Counts at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, and 96
cells/mm^3Dolutegravir 50 mg OD
Absolute CD4+ cell count, Baseline, n=13260 (152 to 863)
Absolute CD4+ cell count, Week 4, n=12578 (374 to 903)
Absolute CD4+ cell count, Week 8, n=12645 (364 to 1118)
Absolute CD4+ cell count, Week 12, n=12589 (303 to 1144)
Absolute CD4+ cell count, Week 16, n=12573 (436 to 1156)
Absolute CD4+ cell count, Week 24, n=12634 (448 to 1339)
Absolute CD4+ cell count, Week (Wk) 36, n=11706 (534 to 1351)
Absolute CD4+ cell count, Week 48, n=11666 (537 to 939)
Absolute CD4+ cell count, Week 60, n=11702 (567 to 1266)
Absolute CD4+ cell count, Week 72, n=11823 (620 to 1315)
Absolute CD4+ cell count, Week 84, n=11907 (512 to 1341)
Absolute CD4+ cell count, Week 96, n=11843 (339 to 1436)
Change from Baseline CD4+ cell count, Week 4, n=12162 (-158 to 365)
Change from Baseline CD4+ cell count, Week 8, n=12247 (44 to 551)
Change from Baseline CD4+ cell count, Wk 12, n=12263 (-17 to 500)
Change from Baseline CD4+ cell count, Wk 16, n=12226 (-248 to 629)
Change from Baseline CD4+ cell count, Wk 24, n=12264 (86 to 762)
Change from Baseline CD4+ cell count, Wk 36, n=11480 (174 to 774)
Change from Baseline CD4+ cell count, Wk 48, n=11311 (-80 to 541)
Change from Baseline CD4+ cell count, Wk 60, n=11382 (5 to 708)
Change from Baseline CD4+ cell count, Wk 72, n=11519 (260 to 651)
Change from Baseline CD4+ cell count, Wk 84, n=11543 (94 to 792)
Change from Baseline CD4+ cell count, Wk 96, n=11467 (-65 to 859)
SecondaryAbsolute Values and Change From Baseline in Cluster of Differentiation 8+ (CD8+) Cell Counts at Weeks 4, 12, 16, 24, 48, and 96

The absolute value for CD48+ cell count (cells per millimeters cubed \[mm\^3\]) was assessed at Baseline, Week 4, Week 12, Week 16, Week 24, Week 48, and Week 96. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Weeks 4, 12, 16, 24, 48, and 96
Reported as:
Median · cells/mm^3
Absolute Values and Change From Baseline in Cluster of Differentiation 8+ (CD8+) Cell Counts at Weeks 4, 12, 16, 24, 48, and 96
cells/mm^3Dolutegravir 50 mg OD
Absolute CD8+ cell count, Baseline, n=13757 (276 to 2945)
Absolute CD8+ cell count, Week 4, n=12874 (542 to 1984)
Absolute CD8+ cell count, Week 12, n=12865 (419 to 1472)
Absolute CD8+ cell count, Week 16, n=12706 (478 to 1818)
Absolute CD8+ cell count, Week 24, n=11876 (434 to 1634)
Absolute CD8+ cell count, Week 48, n=11708 (530 to 1318)
Absolute CD8+ cell count, Week 96, n=11842 (249 to 1582)
Change from Baseline CD8+ cell count, Week 4, n=12104 (-1123 to 1060)
Change from Baseline CD8+ cell count,Week 12, n=11-53 (-1627 to 631)
Change from Baseline CD8+ cell count,Week 16, n=11-35 (-1614 to 684)
Change from Baseline CD8+ cell count,Week 24, n=11235 (-418 to 710)
Change from Baseline CD8+ cell count,Week 48, n=11106 (-747 to 441)
Change from Baseline CD8+ cell count,Week 96, n=1185 (-424 to 677)
SecondaryNumber of Participants With Post-Baseline HIV-1-associated Conditions, Including Recurrences

The number of participants who reported a new or recurrent Centers for Disease Control and Prevention (CDC) Class B or Class C condition was assessed from Baseline though the date the last participant completed Week 96 + the follow-up visit (if applicable). Category (CAT) A: one or more of the following conditions (CON), without any CON listed in Categories B and C: asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have a clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C: the clinical CON listed in the AIDS surveillance case definition.

Time frame:
Baseline through the date the last participant completed Week 96 + follow-up visit (if applicable)
Reported as:
Number · participants
Number of Participants With Post-Baseline HIV-1-associated Conditions, Including Recurrences
participantsDolutegravir 50 mg OD
New CDC Category B event0
Recurring CDC Category B event0
New CDC Category C event0
Recurring CDC Category C event0
SecondaryThe Numbers of Participants (Par.) With Clinical Adverse Events or Laboratory Abnormalities

An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs/SAEs. Any abnormal laboratory test result (hematology, clinical chemistry, or urinalysis) or other safety assessments (e.g., electrocardiograms \[ECGs\], radiological scans, vital sign measurements), including those that worsen from Baseline, and were felt to be clinically significant in the medical and scientific judgment of the investigator, were recorded as AEs or SAEs. Clinically suspected cases of hypersensitivity to ABC were also SAEs.

Time frame:
Baseline (BL) through the date the last participant completed Week (W) 96 + the follow-up visit (if applicable)
Reported as:
Number · participants
The Numbers of Participants (Par.) With Clinical Adverse Events or Laboratory Abnormalities
participantsDolutegravir 50 mg OD
Any AE13
Clinical chemistry toxicities12
Hematology toxicities3
Abnormal ECG (clinically significant)0
SecondaryNumber of Participants With Treatment-emergent Genotypic and Phenotypic Resistance to DTG and Other Antiretroviral Therapy (ART)

The number of participants with treatment-emergent genotypic and phenotypic resistance to integrase inhibitors (INIs), nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transctiptase inhibitors (NNRTIs), and protease inhibitors (PIs) was assessed.

Time frame:
Baseline through the date the last participant completed Week 96
Reported as:
Number · participants
Number of Participants With Treatment-emergent Genotypic and Phenotypic Resistance to DTG and Other Antiretroviral Therapy (ART)
participantsDolutegravir 50 mg OD
Treatment-emergent genotypic resistance0
Treatment-emergent phenotypic resistance0

Adverse events

Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of the study medication to the date the last participant completed Week 96+ follow-up visit (if applicable).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dolutegravir 50 mg OD—2/13 (15.4%)13/13 (100%)
Most frequent serious events
Most frequent serious events
EventDolutegravir 50 mg OD
PharyngitisInfections and infestations1/13
CholecystitisHepatobiliary disorders1/13
Most frequent other events
Showing 10 of 65
Most frequent other events
EventDolutegravir 50 mg OD
HeadacheNervous system disorders7/13
Upper respiratory tract infectionInfections and infestations5/13
DiarrhoeaGastrointestinal disorders4/13
HaemorrhoidsGastrointestinal disorders3/13
FatigueGeneral disorders3/13
Rhinitis allergicRespiratory, thoracic and mediastinal disorders3/13
Procedural painInjury, poisoning and procedural complications3/13
Musculoskeletal painMusculoskeletal and connective tissue disorders3/13
FolliculitisInfections and infestations2/13
PharyngitisInfections and infestations2/13

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Dolutegravir 50 mg OD
Mean40.2 ± 6.90
Sex: Female, Male
Sex: Female, Male(Participants)Dolutegravir 50 mg OD
Female0
Male13
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Dolutegravir 50 mg OD
White13
Baseline plasma human immunodeficiency virus-1 (HIV-1) ribonucleic acid (RNA)
Baseline plasma human immunodeficiency virus-1 (HIV-1) ribonucleic acid (RNA)(log10 copies/mL)Dolutegravir 50 mg OD
Median4.73 (3.60 to 6.57)
Number of participants with Baseline plasma HIV-1 RNA <=100000 copies/mL and >100000 copies/mL
Number of participants with Baseline plasma HIV-1 RNA <=100000 copies/mL and >100000 copies/mL(Participants)Dolutegravir 50 mg OD
<=100000 copies/mL8
>100000 copies/mL5
08

Study locations

3 sites
  • GSK Investigational Site
    Los Angeles, California 90069, United States
  • GSK Investigational Site
    San Diego, California 92103, United States
  • GSK Investigational Site
    Providence, Rhode Island 02906, United States
09

References and documents

Publications

  • Letendre S, Mills A, Tashima K, et al. Distribution and antiviral activity in cerebrospinal fluid (CSF) of the integrase inhibitor, dolutegravir (DTG): ING116070 week 16 results. Published at: Conference on Retroviruses and Opportunistic Infections - 20th Annual; March 3-6, 2013; Atlanta, GA.
  • Letendre S, Mills A, Tashima K, et al. CSF penetration and antiviral activity of the integrase inhibitor, dolutegravir (DTG, GSK1349572): ING116070 week 16 results. Published at: International Symposium on Neuropsychiatry & HIV - 6th; May 9-10, 2013; Barcelona, Spain
  • Letendre SL, Mills AM, Tashima KT, Thomas DA, Min SS, Chen S, Song IH, Piscitelli SC; extended ING116070 study team. ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis. 2014 Oct;59(7):1032-7. doi: 10.1093/cid/ciu477. Epub 2014 Jun 18. PubMed 24944232 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Oct 2012 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2011
First posted
Dec 26, 2011
Start
Jan 2012
Primary completionActual
Oct 2012
CompletionActual
May 2014
Results first posted
Nov 25, 2013
Last update
Feb 25, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01499199
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Dec 26, 2011
Start date
Jan 2012
Primary completion
Oct 2012
Completion
May 2014
Results posted
Nov 25, 2013
Last update
Feb 25, 2015

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dolutegravir

Start the discussion